Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04910581
Other study ID # D20180404
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 23, 2023
Est. completion date January 12, 2024

Study information

Verified date February 2024
Source Assistance Publique - Hôpitaux de Paris
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Wilson disease is a hereditary hepatic and neurological disease associated with copper accumulation. Neurological symptoms are of extra-pyramidal, cerebellar and dystonic origin. Dysarthria is one of the debilitating symptoms of Wilson disease poorly responsive to pharmacological treatment. The most common form is a dystonic hyperkinetic Dysarthria. Pathophysiology of dystonia is still not elucidated. Motor cortex hyperexcitability has been demonstrated in various forms of dystonia. Furthermore, rTMS inhibitory applied over motor cortex has been shown to transitory reduce dystonic symptoms in various forms of dystonia. In the present study, we investigate the effect of a single 1Hz 20-minutes inhibitory rTMS session applied over the motor laryngeal cortex on dyasarthria is the main kinetic dysarthria has been shown to be associated with inhibition of laryngeal motor cortex in Parkinson disease.


Description:

A consecutive series of Wilson disease patients with dystonic hyperkinetic dysarthria will be prospectively recruited. Patients will receive 3 days apart to two rTMS sessions. rTMS procedures will be performed with a figure of eight coiled. A single 20-minutes 1 Hz biphasic stimulation (1200 pulses) session will be applied over the laryngeal motor cortex. A brain imaging positioning device will be used during all the procedure A second stimulation session will be performed 3 days apart. Patients will be centrally randomized to receive first either the active stimulation (80% of the resting motor threshold) or the sham stimulation (using a visually identical coil to reproduce the click sound and the scalp sensation of the active coil). A TMS evaluation of cortical silent period over the left motor cortex will be performed before the first rTMS session. Before and immediately after each stimulation (active or sham) patient will received an clinical evaluation including Clinical Assessment Battery for Dysarthria intelligibility score, "A" phonation time, diadococinesia , bucco-linguo-facial motricity score and UWDRS. A standard 20-minutes EEG will be performed before the first rTMS session and immediately after the second rTMS session.


Recruitment information / eligibility

Status Completed
Enrollment 18
Est. completion date January 12, 2024
Est. primary completion date January 12, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Conseting adult patients with social insurance - Wilson disease with dystonic hyperkinetic dysarthria - Stable pharmacological therapy n the last 6 monts - Brain MRI in the previous 6 months, without additional brain lesion - Patients that did not receive botulinium toxin in the previous 4 months Exclusion Criteria: - Incapacitated adult - Previous mdedical history of epilepsia - Pregnancy or breastfeeding - Brain lesion outside basal ganglia on brain MRI - Patient consider by the investigator not able to sustain an 30 minutes rTMS session without moving - Vocal chord lesion - Previous history of laryngeal surgery - rTMS contra indication

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
rTMS
Single 30-minutes session of 1Hz rTMS applied over the left laryngeal motor cortex
Sham stimulation
Single 30-minutes session of sham stimulation applied over the left laryngeal motor cortex

Locations

Country Name City State
France Service de Neurologie, Hopital Fondation Adolphe de Rothschild Paris
France Service de Physiologie Clinique-Explorations Fonctionnelles, AP-HP, Hôpital Lariboisière Paris

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Improvement of the Clinical Assessment Battery for Dysarthria intelligibility score Improvement of the Clinical Assessment Battery for Dysarthria intelligibility score with active stimulation in comparison to sham stimulation within 30 minutes after stimulation session at Day1 and Day4
Secondary Improvement of the Clinical Assessment Battery for Dysarthria intelligibility sub-scores Improvement of the Clinical Assessment Battery for Dysarthria intelligibility sub-scores with active stimulation in comparison to sham stimulation within 30 minutes after stimulation session at Day1 and Day4
Secondary the "A" phonation time Improvement of the "A" phonation time with active stimulation in comparison to sham stimulation within 30 minutes after stimulation session at Day1 and Day4
Secondary Improvement of the diadococinesia Improvement of the diadococinesia with active stimulation in comparison to sham stimulation within 30 minutes after stimulation session at Day1 and Day4
Secondary Improvement of text reading Improvement of text reading with active stimulation in comparison to sham stimulation within 30 minutes after stimulation session at Day1 and Day4
Secondary Improvement of bucco-linguo-facial motricity Improvement of bucco-linguo-facial motricity with active stimulation in comparison to sham stimulation within 30 minutes after stimulation session at Day1 and Day4
Secondary Improvement bucco-linguo-facial motricity Improvement bucco-linguo-facial motricity with active stimulation in comparison to sham stimulation within 30 minutes after stimulation session at Day1 and Day4
Secondary Correlation between clinical Assessment Battery for Dysarthria intelligibility score and UWDRS, and MRI brain atrophy and basal ganglia lesions Correlation of changes in the Battery for Dysarthria intelligibility score with clinical parameters (age at diagnosis, delay related to first symptoms, degree of neurological handicap and brain lesions observed on basline MRI (cortical atrophy and lesions of the basal ganglia) at Day1 and Day4
Secondary Side effects of rTMS Any side effect after stimulation (fatigue, neck pain, neck stiffness, dizziness, nausea, itching, mood disorders ..) will be collected following the stimulation.
Side effects of rTMS are rare. Most often they are minor and transient.
within few hours after stimulation session at Day1 and Day4
See also
  Status Clinical Trial Phase
Completed NCT04573309 - Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840 Phase 2
Completed NCT03539952 - Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's Disease Phase 3
Active, not recruiting NCT04884815 - Study of UX701 Gene Transfer for the Treatment of Wilson Disease Phase 1/Phase 2
Not yet recruiting NCT03659331 - A Controlled Study of Potential Therapeutic Effect of Oral Zinc in Manifesting Carriers of Wilson Disease N/A
Recruiting NCT05687474 - Baby Detect : Genomic Newborn Screening
Completed NCT04965571 - Clinical Features and Outcome of Wilson's Disease With Generalized Epilepsy in Chinese Patients
Terminated NCT05047523 - Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease Phase 3
Completed NCT04526210 - Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants Phase 1
Completed NCT00004338 - Study of Zinc for Wilson Disease Phase 4
Enrolling by invitation NCT03655223 - Early Check: Expanded Screening in Newborns
Completed NCT02273596 - Efficacy and Safety Study of WTX101 (ALXN1840) in Adult Wilson Disease Patients Phase 2
Completed NCT02763215 - The Assessment of Copper Parameters in Wilson Disease Participants on Standard of Care Treatment
Recruiting NCT05444127 - Oral Health and Wilson's Disease: SOMAWI
Completed NCT04408300 - Study of Retinal Vascular Parameters in Patients With Wilson's Disease N/A
Active, not recruiting NCT05783687 - Real World Evidence Study in Subjects With Wilson's Disease
Terminated NCT04909346 - Adeno-Associated Virus (AAV) Antibody Study in Subjects OTC Deficiency, GSDIa, and Wilson Disease
Completed NCT03867526 - Establishment of Human Cellular Disease Models for Wilson Disease
Enrolling by invitation NCT03589820 - Plasma Exchange and Continuous Hemodiafiltration in Treatment of Wilson's Disease-related Liver Failure N/A
Completed NCT04526197 - Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants. Phase 1
Not yet recruiting NCT06430359 - Circadian Variation of Urinary Copper Excretion in Wilson Disease Patients